3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Multiple Myeloma
2
Lymphoma
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Neuroendocrine Tumors
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Leukemia, B-Cell
1
Leukemia
1
Hematologic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Advanced Solid Tumors
1
Interventions
tislelizumab
4
talazoparib
4
pembrolizumab
4
Docetaxel
4
Nivolumab
3
PM 01183
2
MLN 8237
2
Itraconazole
2
Fluorouracil
2
Cisplatin
2
Carboplatin
2
zimberelimab
1
utomilumab
1
urelumab
1
ulixertinib
1
trifluridine tipiracil drug combination
1
sitravatinib
1
sapanisertib
1
pexidartinib
1
pevonedistat
1
peposertib
1
niraparib
1
mogamulizumab
1
lenvatinib
1
ixabepilone
1
eribulin
1
durvalumab
1
dalotuzumab
1
avelumab
1
ascrinvacumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Advanced Solid Tumors
×
Antiemetics
×
Clear all
NCT06242691
2026-06-05
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2
Completed
13 enrolled
21 charts